2型糖尿病合并动脉粥样硬化性心血管疾病患者的心血管表型聚类分析:精准医学的潜在方法
本研究利用TECOS试验(n=14671)中2型糖尿病合并动脉粥样硬化性心血管疾病(ASCVD)患者的数据,通过聚类分析机器学习算法识别出四种临床表型。主要复合终点在四个聚类中的发生率分别为11.6%、8.6%、10.3%和16.8%,最高风险聚类(IV)与最低风险聚类(II)的风险比为2.74(95%CI 2.29-3.29)。EXSCEL试验重复出相似表型和结局。
要点
- 聚类分析识别出四种临床表型:冠脉病变白人男性、低BMI亚洲患者、非冠脉ASCVD女性、心衰伴肾功能不全患者。
- 最高风险聚类(IV)与最低风险聚类(II)的主要复合终点风险比为2.74(95%CI 2.29-3.29)。
- EXSCEL试验重复出相似表型和结局,提示聚类分析可用于精准医学分层。
核心结论
- 在2型糖尿病合并ASCVD患者中,聚类分析识别出四种临床 distinct 表型,且与心血管结局相关。
研究设计与样本
- 基于TECOS试验(n=14671)数据,使用40个基线变量进行聚类分析,并通过Cox比例风险模型评估聚类与主要复合终点的关联。
- 在EXSCEL试验中重复验证结果。
主要发现
- 聚类I:冠脉病变高发的白人男性;聚类II:低BMI的亚洲患者;聚类III:非冠脉ASCVD的女性;聚类IV:心衰伴肾功能不全患者。
- 主要复合终点在聚类I至IV的发生率分别为11.6%、8.6%、10.3%和16.8%。
- 最高风险聚类(IV)与最低风险聚类(II)的粗风险比为2.74(95%CI 2.29-3.29)。
关键数值与推荐
- 主要复合终点定义为心血管死亡、非致死性心肌梗死、非致死性卒中或不安定心绞痛住院。
- 中位随访时间为3.0年。
临床怎么用
- 聚类分析可能有助于识别2型糖尿病合并ASCVD患者中的高风险亚组,为精准医学和临床试验设计提供依据。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Phenotypic heterogeneity among patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) is ill defined. We used cluster analysis machine-learning algorithms to identify phenotypes among trial participants with T2DM and ASCVD. RESEARCH DESIGN AND METHODS: We used data from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study (n = 14,671), a cardiovascular outcome safety trial comparing sitagliptin with placebo in patients with T2DM and ASCVD (median follow-up 3.0 years). Cluster analysis using 40 baseline variables was conducted, with associations between clusters and the primary composite outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina) assessed by Cox proportional hazards models. We replicated the results using the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. RESULTS: Four distinct phenotypes were identified: cluster I included Caucasian men with a high prevalence of coronary artery disease; cluster II included Asian patients with a low BMI; cluster III included women with noncoronary ASCVD disease; and cluster IV included patients with heart failure and kidney dysfunction. The primary outcome occurred, respectively, in 11.6%, 8.6%, 10.3%, and 16.8% of patients in clusters I to IV. The crude difference in cardiovascular risk for the highest versus lowest risk cluster (cluster IV vs. II) was statistically significant (hazard ratio 2.74 [95% CI 2.29-3.29]). Similar phenotypes and outcomes were identified in EXSCEL. CONCLUSIONS: In patients with T2DM and ASCVD, cluster analysis identified four clinically distinct groups. Further cardiovascular phenotyping is warranted to inform patient care and optimize clinical trial designs.
引用
- Sharma A, Zheng Y, Ezekowitz JA, et al. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes Care. 2022. PMID: 34716214. doi:10.2337/dc20-2806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。